BioTime launches all-stock bid to acquire Geron's stalled stem cell programme
This article was originally published in Scrip
After hiring Geron's former president and CEO to run an acquisition-focused subsidiary, BioTime has made a public bid for the regenerative medicine programme that Geron put on hold almost a year ago, offering an all-stock deal for embryonic stem cell technology previously investigated as a treatment for acute spinal cord injuries.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.